[{"indications": "Indications\u00a0treatment of mild to moderate ulcerative colitis and maintenance\r\nof remission; see also under preparations", "name": "MESALAZINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "1 Gastro-intestinal system", "1.5 Chronic bowel disorders", "1.5.1 Aminosalicylates"], "cautions": "Cautions\u00a0\n(From 1.5.1 Aminosalicylates: British National Formulary)\nCautions\u00a0Renal function should be monitored before starting an oral aminosalicylate, at 3 months of treatment, and then annually during treatment (more frequently in renal impairment). Blood disorders can occur with aminosalicylates (see recommendation below).; elderly; interactions: Appendix 1\r\n(aminosalicylates)Blood disorders\u00a0See %s\n(From 1.5.1 Aminosalicylates: British National Formulary)\nBlood disordersPatients receiving aminosalicylates should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment. A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia.", "side-effects": "Side-effects\u00a0see notes above", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2168.htm", "doses": ["See under preparations, below", "The delivery characteristics of oral mesalazine preparations may vary; these preparations should\r\nnot be considered interchangeable"], "pregnancy": "Pregnancy\u00a0negligible quantities cross placenta"}]